| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | 14.8 | 13.9 |
| Gross profit | 9.4 | 9.2 |
| Profit before tax | -3.9 | 2.0 |
| Net income | -3.9 | 2.0 |
| EPS (diluted, $ a share) | $-0.20 | $-0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +6.9% |
|---|---|
| Gross margin | 63.6% |
| Operating margin | -26.5% |
10-Q filed with the SEC, NASDAQ: AYTU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aytu Biopharma, Inc: key numbers
- Share price
- $1.82Close, Nov 16
- Market cap
- $19.8M
- Shares outstanding
- 10.87MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aytu Biopharma, Inc
All →Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.
- Value
- $56M
- Counterparty
- Rosemont Pharmaceuticals Holdings, Inc.
“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”
Josh Disbrow, Chief Executive Officer of Aytu
“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
Josh Disbrow, Chief Executive Officer of Aytu
Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.
- Counterparty
- Rosemont Pharmaceuticals Holdings, Inc.
Aytu Biopharma Financial Results
Aytu BioPharma reported fiscal 2026 fourth quarter net revenue of $16.1 million, a 6.4% increase year-over-year, driven by the commercial launch of EXXUA which generated $3.9 million in the quarter. For the full fiscal year 2026, net revenue was $57.6 million with a net loss of $14.3 million, as the company prioritized investments in its EXXUA launch over its legacy ADHD and pediatric portfolios.
- Term
- FY2026
- Earnings call
- Sep 22, 2026, 4:30 PM ET
“Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence in this exciting opportunity.”
Josh Disbrow, Chief Executive Officer of Aytu